MIM
KRON

MetLife Investment Management’s Kronos Bio KRON Stock Holding History

MetLife Investment Management’s Portfolio KRON Stock Details KRON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-25,568
Closed -$85.7K – 2838
2022
Q3 		$85.7K Buy
+25,568
New +$115K ﹤0.01% 2715
2022
Q2 		– Sell
-24,534
Closed -$177K – 2886
2022
Q1 		$177K Buy
24,534
+9,055
+58% +$77.2K ﹤0.01% 2427
2021
Q4 		$210K Hold
15,479
– – ﹤0.01% 2022
2021
Q3 		$324K Hold
15,479
– – ﹤0.01% 1778
2021
Q2 		$371K Buy
15,479
+8,583
+124% +$217K ﹤0.01% 1751
2021
Q1 		$202K Hold
6,896
– – ﹤0.01% 2045
2020
Q4 		$206K Buy
+6,896
New +$216K ﹤0.01% 1970

Other funds holding KRON

OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VVA
Vida Ventures Advisors Boston, Massachusetts $29.4M AUM 93.58% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
WCM
Wildcat Capital Management New York $229M AUM 132.65% 1-Year Est. Return

MetLife Investment Management's KRON Position: Q4 2022 in Review

MetLife Investment Management sold out of Kronos Bio (KRON) in Q4 2022, closing a stake of 25,568 shares — an estimated $85.7K sold.

MetLife Investment Management first reported a position in KRON in Q4 2020 and held it in 7 quarters. The position peaked at $371K in Q2 2021. 97 funds tracked by Wall St. Rank hold KRON as of Q4 2022.

  • MetLife Investment Management reported no remaining Kronos Bio position as of Q4 2022 after selling out during the quarter.
  • MetLife Investment Management sold 25,568 Kronos Bio shares in Q4 2022, an estimated $85.7K.
  • MetLife Investment Management first reported a position in Kronos Bio in Q4 2020 and held it in 7 quarters.
  • MetLife Investment Management's Kronos Bio position peaked at $371K in Q2 2021.
  • 97 funds tracked by Wall St. Rank held Kronos Bio as of Q4 2022.

Based on MetLife Investment Management's 13F filing for Q4 2022, filed 15 Feb 2023.